KNSAKNSAHealthcare · Drug Manufacturers - Specialty & Generic

KNSA Stock Forecast: Kiniksa Pharmaceuticals International Plc Price Predictions for 2026-2027

Last close, 18 Nov 2026
$95
−0.06% on the day

The 7 Wall Street analysts covering Kiniksa Pharmaceuticals International Plc hold a median 12-month price target of $102 — +7.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 98 of 100 as at 17 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$7.4B
Ticker Nerd rank
98/ 100
Median analyst target
$102
Analysts covering
7
Revenue$243.6M+55.4% y/y
Operating income$27.2M
Net income$25.4M
Free cash flow$46.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.7%
1M
+20.9%
YTD
+130.4%
1Y
+130.3%
From 52W high
−3.8%
From 52W low
+150.7%
$38
$99
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KNSA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kiniksa Pharmaceuticals International Plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
98/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
100
Volatility
96
Value
96
Quality
91
Growth
83
Revisions
82
Accruals
61
Issuance
55
Size
18

Momentum (100): The shares have been drifting up relative to others.

Issuance (55): The company has been issuing shares or taking on financing, diluting existing holders.

Size (18): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

KNSA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KNSA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100$120$140Jan 26Apr 26Jul 26Oct 26KNSAHigh $134Median $102Low $98

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $98Median $102High $134

The green dot is the last close — the median target sits +7.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 11 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
30 Oct 2026JP MorganMaintainsOverweight$107 → $122
28 Oct 2026Goldman SachsMaintainsBuy$90 → $101
28 Oct 2026WedbushMaintainsOutperform$99 → $102
28 Oct 2026Wells FargoMaintainsOverweight$87 → $110
30 July 2026Goldman SachsMaintainsBuy—
30 July 2026Goldman SachsMaintainsBuy$75 → $90
29 July 2026Canaccord GenuityMaintainsBuy—
29 July 2026Canaccord GenuityMaintainsBuy$64 → $98
29 July 2026CitigroupMaintainsBuy—
29 July 2026CitigroupMaintainsBuy$60 → $100
29 July 2026JP MorganMaintainsOverweight$72 → $107
29 July 2026JP MorganMaintainsOverweight—
29 July 2026WedbushMaintainsOutperform$72 → $99
29 July 2026WedbushMaintainsOutperform—
23 July 2026Goldman SachsMaintainsBuy—
23 July 2026Goldman SachsMaintainsBuy$60 → $75
13 July 2026Wells FargoMaintainsOverweight$57 → $74
13 July 2026Wells FargoMaintainsOverweight—
29 June 2026WedbushMaintainsOutperform—
29 Apr 2026Canaccord GenuityMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

KNSA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

KNSA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, Kiniksa Pharmaceuticals International Plc returned +130.3% against +12.2% for the S&P 500, dividends included.

KNSA vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Jan 26Apr 26Jul 26Oct 26KNSAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KNSA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+29.2%
Analysts raising
1
Analysts cutting
0
Fundamentals

Kiniksa Pharmaceuticals International Plc (KNSA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
71.4×

Cheaper than 10% of US stocks

Price / sales
7.8×

Cheaper than 15% of US stocks

Price / book
10.4×

Cheaper than 8% of US stocks

EV / EBITDA
51.7×

Cheaper than 4% of US stocks

Growth & margins
Revenue growth (YoY)
58.1%

Higher than 88% of US stocks

Earnings growth (YoY)
156.8%

Higher than 88% of US stocks

Gross margin
54.2%

Higher than 67% of US stocks

Operating margin
13.8%

Higher than 72% of US stocks

Net margin
11.6%

Higher than 72% of US stocks

Returns & dividend
Return on equity
17.6%

Higher than 78% of US stocks

Return on assets
9.6%

Higher than 91% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Kiniksa Pharmaceuticals International Plc (KNSA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Kiniksa Pharmaceuticals International Plc has a market value of $7.4B and an enterprise value of $6.8B.

  • Revenue in the twelve months to 30 June 2026: $840.8M. The latest quarter grew 58.1% year on year.

  • Net income over the same four quarters: $80.7M, a 9.6% net margin.

  • Diluted earnings per share, trailing twelve months: $0.97.

  • Free cash flow in the twelve months to 30 June 2026: $182.8M.

  • Kiniksa Pharmaceuticals International Plc spent $11.1M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 78.0M.

  • Trailing P/E: 71.4×; forward P/E: 46.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Kiniksa Pharmaceuticals International Plc employs 366 people — $2.3M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Nov 2026

Data provided by Twelve Data

Peers

KNSA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
KNSAKiniksa Pharmaceuticals International Plc$7.4B98
AMRXAmneal Pharmaceuticals, Inc.$7.4B83
ALKSAlkermes Plc$7.5B70
LNTHLantheus Holdings, Inc.$6.6B98
SUPN.1Supernus, Inc.$6.0B89
LQDALiquidia Corp.$5.1B97
ELANElanco Animal Health, Inc.$12.9B97

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kiniksa Pharmaceuticals International Plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KNSA news & analysis

Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London

GlobeNewsWire · 11 Nov 2026neutral

Kiniksa Pharmaceuticals announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 16, 2026, at 11:00 a.m. GMT (6:00 a.m. ET).

Why it matters — The announcement provides KNSA watchers with the timing of an upcoming management appearance at an investor conference.

Here's Why Kiniksa Pharmaceuticals International, plc (KNSA) is a Strong Momentum Stock

Zacks Investment Research · 4 Nov 2026positive

A Zacks Investment Research headline describes Kiniksa Pharmaceuticals International (KNSA) as a strong momentum stock. The excerpt introduces Zacks Style Scores as a feature of its Premium research service for identifying stocks across investing styles.

Why it matters — KNSA watchers may note the positive momentum framing and the cited Zacks research feature.

Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors

The Motley Fool · 27 Oct 2026positive

Kiniksa raised its 2026 revenue guidance to over $1.045 billion. ARCALYST penetration among patients with multiple recurrences reached 23%.

Why it matters — The updated revenue guidance and ARCALYST penetration are key operating developments for KNSA watchers.

What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings Call

MarketBeat · 27 Oct 2026positive

Kiniksa raised its full-year 2026 revenue guidance after reporting 58% year-over-year growth in third-quarter ARCALYST revenue. The company also cited continued expansion of the drug's use for recurrent pericarditis and progress in its clinical pipeline.

Why it matters — The update provides KNSA watchers with information on ARCALYST's recent revenue growth, expanded use, and the company's outlook and pipeline progress.

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2026 Earnings Call Transcript

Seeking Alpha · 27 Oct 2026neutral

Seeking Alpha published a transcript of Kiniksa Pharmaceuticals International, plc’s Q3 2026 earnings call. The provided excerpt contains no further details about the call.

Why it matters — The transcript may provide KNSA watchers with management’s discussion, but the excerpt itself does not include specific company updates.

FAQ

Frequently asked questions about KNSA stock

What is the KNSA stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Kiniksa Pharmaceuticals International Plc have a median 12-month price target of $102, with estimates ranging from $98 to $134. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KNSA stock a buy right now?

Of the 7 analysts covering Kiniksa Pharmaceuticals International Plc, 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kiniksa Pharmaceuticals International Plc 98 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KNSA?

As at 17 Nov 2026, Kiniksa Pharmaceuticals International Plc ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).

Will KNSA stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +7.3% from the last close, and Ticker Nerd's factor model ranks Kiniksa Pharmaceuticals International Plc 98 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KNSA stock forecast for 2030?

No analyst covering Kiniksa Pharmaceuticals International Plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KNSA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $98 to $134 over the next 12 months.

How has KNSA stock performed over the past year?

Kiniksa Pharmaceuticals International Plc returned +130.3% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kiniksa Pharmaceuticals International Plc do?

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares represents an equity interest in Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company focused on discovering, developing, and commercializing therapies for immune-mediated and inflammatory diseases. The company’s current portfolio centers on products and candidates such as ARCALYST, a marketed interleukin-1 trap used in recurrent pericarditis and related inflammatory conditions, alongside additional clinical-stage programs in immunology and inflammation.

What is the latest news on KNSA?

The most recent item we track (GlobeNewsWire, 11 Nov 2026): "Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London". Kiniksa Pharmaceuticals announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 16, 2026, at 11:00 a.m. GMT (6:00 a.m. ET).

Company

About Kiniksa Pharmaceuticals International Plc.

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares represents an equity interest in Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company focused on discovering, developing, and commercializing therapies for immune-mediated and inflammatory diseases. The company’s current portfolio centers on products and candidates such as ARCALYST, a marketed interleukin-1 trap used in recurrent pericarditis and related inflammatory conditions, alongside additional clinical-stage programs in immunology and inflammation. Kiniksa serves patients and healthcare providers in the United States, the United Kingdom, and other international markets, with emphasis on specialized treatments for cardiovascular and autoimmune disorders. The company’s role in the healthcare sector is defined by its concentration on targeted biologic medicines that address serious conditions with limited treatment options. Headquartered in London, Kiniksa Pharmaceuticals International, plc operates as a commercial-stage biopharmaceutical business within the global specialty drug market.

CEO Mr. Sanjiv K. Patel · 366 employees · United Kingdom · https://www.kiniksa.com